| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| CTVACorteva, Inc. | 47.64B | 70.50 | 54.23 | -1.85% | 9.19% | 6.3% | 3.25% | 0.11 |
| CTA-PAEIDP, Inc. | 47.43B | 54.65 | 42.04 | -1.85% | 9.2% | 6.4% | 3.26% | 0.11 |
| RKDAArcadia Biosciences, Inc. | 5.24M | 2.40 | -0.47 | 13.27% | -97.95% | -93.09% | 0.02 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 5.41M | 3.19M | 4.03M | 1.46M | 1.17M | 8.03M | 6.78M | 7.42M | 4.45M | 5.04M |
| Revenue Growth % | -0.22% | -0.41% | 0.26% | -0.64% | -0.2% | 5.87% | -0.16% | 0.09% | -0.4% | 0.13% |
| Cost of Goods Sold | 892K | 895K | 283K | 661K | 885K | 5.2M | 8.71M | 6.1M | 2.17M | 2.96M |
| COGS % of Revenue | 0.16% | 0.28% | 0.07% | 0.45% | 0.76% | 0.65% | 1.28% | 0.82% | 0.49% | 0.59% |
| Gross Profit | 4.52M | 2.29M | 3.74M | 803K | 284K | 2.83M | -1.93M | 1.32M | 2.28M | 2.08M |
| Gross Margin % | 0.84% | 0.72% | 0.93% | 0.55% | 0.24% | 0.35% | -0.28% | 0.18% | 0.51% | 0.41% |
| Gross Profit Growth % | -0.09% | -0.49% | 0.63% | -0.79% | -0.65% | 8.98% | -1.68% | 1.68% | 0.73% | -0.09% |
| Operating Expenses | 20.09M | 20.91M | 18.06M | 17.67M | 19.66M | 15.61M | 33.6M | 15.32M | 8.38M | 5.73M |
| OpEx % of Revenue | 3.71% | 6.56% | 4.49% | 12.07% | 16.82% | 1.94% | 4.96% | 2.07% | 1.88% | 1.14% |
| Selling, General & Admin | 11.12M | 12.25M | 10.65M | 11.6M | 13.57M | 16.47M | 22.94M | 15.04M | 8.23M | 9.64M |
| SG&A % of Revenue | 2.05% | 3.84% | 2.65% | 7.93% | 11.61% | 2.05% | 3.38% | 2.03% | 1.85% | 1.91% |
| Research & Development | 8.97M | 8.66M | 7.41M | 6.07M | 7.1M | 7.96M | 3.89M | 1.51M | 64K | 53K |
| R&D % of Revenue | 1.66% | 2.72% | 1.84% | 4.15% | 6.07% | 0.99% | 0.57% | 0.2% | 0.01% | 0.01% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | -1M | -8.81M | 6.77M | -1.22M | 84K | -3.96M |
| Operating Income | -15.56M | -18.62M | -14.31M | -16.87M | -19.38M | -12.78M | -35.53M | -14.01M | -6.1M | -3.65M |
| Operating Margin % | -2.87% | -5.84% | -3.56% | -11.52% | -16.58% | -1.59% | -5.24% | -1.89% | -1.37% | -0.72% |
| Operating Income Growth % | -0.03% | -0.2% | 0.23% | -0.18% | -0.15% | 0.34% | -1.78% | 0.61% | 0.56% | 0.4% |
| EBITDA | -15.27M | -18.32M | -14.04M | -16.72M | -19.19M | -12.12M | -34.48M | -13.53M | -5.82M | -3.54M |
| EBITDA Margin % | -2.82% | -5.75% | -3.49% | -11.42% | -16.41% | -1.51% | -5.09% | -1.82% | -1.31% | -0.7% |
| EBITDA Growth % | -0.03% | -0.2% | 0.23% | -0.19% | -0.15% | 0.37% | -1.85% | 0.61% | 0.57% | 0.39% |
| D&A (Non-Cash Add-back) | 294K | 304K | 279K | 154K | 194K | 662K | 1.04M | 479K | 287K | 113K |
| EBIT | -15.27M | -18.28M | -14.93M | -13.47M | -28.87M | -6.1M | -28.75M | -15.23M | -6.02M | -7.61M |
| Net Interest Income | -2.66M | -1.32M | -747K | -2.56M | -5K | -47K | -20K | 289K | 695K | 782K |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 289K | 695K | 782K |
| Interest Expense | 2.66M | 1.32M | 747K | 2.56M | 5K | 47K | 20K | 0 | 0 | 0 |
| Other Income/Expense | -2.37M | -979K | -1.37M | 3.4M | -9.49M | 6.63M | 19.39M | 3.19M | 781K | -661K |
| Pretax Income | -17.93M | -19.6M | -15.68M | -13.47M | -28.87M | -6.15M | -16.13M | -10.81M | -5.32M | -4.31M |
| Pretax Margin % | -3.31% | -6.15% | -3.89% | -9.2% | -24.7% | -0.77% | -2.38% | -1.46% | -1.19% | -0.85% |
| Income Tax | 26K | 25K | 26K | 10K | 2K | -124K | 2K | 14K | 8K | 8K |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 0.76% | 0.91% | 1.42% | 2.63% | 1.63% |
| Net Income | -17.96M | -19.62M | -15.71M | -13.48M | -28.8M | -4.66M | -14.66M | -15.38M | -13.98M | -7.04M |
| Net Margin % | -3.32% | -6.16% | -3.9% | -9.21% | -24.64% | -0.58% | -2.16% | -2.07% | -3.14% | -1.4% |
| Net Income Growth % | 0.02% | -0.09% | 0.2% | 0.14% | -1.14% | 0.84% | -2.15% | -0.05% | 0.09% | 0.5% |
| Net Income (Continuing) | -17.96M | -19.62M | -15.71M | -13.48M | -28.87M | -6.03M | -16.13M | -10.83M | -5.33M | -4.32M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4.78M | -8.66M | -2.72M |
| Minority Interest | 0 | 0 | 0 | 0 | 621K | 827K | 103K | -133K | -138K | 0 |
| EPS (Diluted) | -503.00 | -353.85 | -291.38 | -143.16 | -181.50 | -24.20 | -30.33 | -26.05 | -11.30 | -5.16 |
| EPS Growth % | -0.12% | 0.3% | 0.18% | 0.51% | -0.27% | 0.87% | -0.25% | 0.14% | 0.57% | 0.54% |
| EPS (Basic) | -503.00 | -353.85 | -291.38 | -143.16 | -181.50 | -24.20 | -30.33 | -26.05 | -11.30 | -5.16 |
| Diluted Shares Outstanding | 35.7K | 55.46K | 53.91K | 94.16K | 159.08K | 248.97K | 532.01K | 599.39K | 1.24M | 1.36M |
| Basic Shares Outstanding | 35.7K | 55.46K | 53.91K | 94.16K | 159.08K | 248.97K | 532.01K | 599.39K | 1.24M | 1.36M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 52.02M | 52.22M | 15.05M | 22.88M | 28.44M | 31.7M | 35.39M | 25.4M | 14.97M | 9.24M |
| Cash & Short-Term Investments | 50.24M | 50.56M | 13.02M | 21.82M | 25.33M | 25.67M | 28.68M | 20.64M | 11.64M | 4.24M |
| Cash Only | 23.97M | 2.01M | 9.13M | 12M | 8.42M | 14.04M | 28.68M | 20.64M | 6.52M | 4.24M |
| Short-Term Investments | 26.27M | 48.55M | 3.9M | 9.82M | 16.91M | 11.63M | 0 | 0 | 5.12M | 0 |
| Accounts Receivable | 788K | 533K | 1.24M | 168K | 602K | 1.41M | 1.37M | 1.22M | 514K | 1.18M |
| Days Sales Outstanding | 53.13 | 61.02 | 111.97 | 41.89 | 187.96 | 63.88 | 73.75 | 60.08 | 42.12 | 85.01 |
| Inventory | 294K | 252K | 229K | 181K | 1.79M | 3.81M | 4.43M | 2.32M | 1.96M | 904K |
| Days Inventory Outstanding | 120.3 | 102.77 | 295.35 | 99.95 | 739.9 | 267.62 | 185.81 | 138.86 | 328.74 | 111.36 |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.21M | 858K | 1.99M |
| Total Non-Current Assets | 22.23M | 4.35M | 1.52M | 1.15M | 4.13M | 15.65M | 8.53M | 3.52M | 4.73M | 4.28M |
| Property, Plant & Equipment | 585K | 508K | 299K | 395K | 3.76M | 9.37M | 5.37M | 2.53M | 1.18M | 178K |
| Fixed Asset Turnover | 9.25x | 6.28x | 13.46x | 3.71x | 0.31x | 0.86x | 1.26x | 2.93x | 3.79x | 28.34x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 408K | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 370K | 484K | 40K | 39K | 39K |
| Long-Term Investments | 19.75M | 2.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 1.89M | 1.35M | 1.22M | 753K | 372K | 5.51M | 2.67M | 956K | 3.52M | 4.06M |
| Total Assets | 74.24M | 56.57M | 16.57M | 24.02M | 32.57M | 47.35M | 43.92M | 28.92M | 19.7M | 13.52M |
| Asset Turnover | 0.07x | 0.06x | 0.24x | 0.06x | 0.04x | 0.17x | 0.15x | 0.26x | 0.23x | 0.37x |
| Asset Growth % | 1.98% | -0.24% | -0.71% | 0.45% | 0.36% | 0.45% | -0.07% | -0.34% | -0.32% | -0.31% |
| Total Current Liabilities | 3.45M | 3.13M | 3.52M | 3.05M | 5.71M | 6.31M | 5.04M | 4.21M | 3.59M | 2.56M |
| Accounts Payable | 424K | 222K | 366K | 285K | 492K | 726K | 1.41M | 905K | 801K | 703K |
| Days Payables Outstanding | 173.5 | 90.54 | 472.05 | 157.38 | 202.92 | 50.97 | 59.14 | 54.14 | 134.48 | 86.6 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 24K | 1.14M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 740K | 1000K | 96K | 42K | 8K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 197K | 88K | 1.58M | 306K | 263K | 264K | 296K | 634K | 483K |
| Current Ratio | 15.08x | 16.69x | 4.27x | 7.49x | 4.98x | 5.02x | 7.02x | 6.03x | 4.17x | 3.61x |
| Quick Ratio | 14.99x | 16.61x | 4.20x | 7.43x | 4.67x | 4.42x | 6.14x | 5.48x | 3.63x | 3.25x |
| Cash Conversion Cycle | -0.07 | 73.26 | -64.73 | -15.54 | 724.95 | 280.53 | 200.42 | 144.79 | 236.37 | 109.77 |
| Total Non-Current Liabilities | 30.57M | 31.25M | 5.04M | 8.15M | 18.54M | 12.48M | 7.68M | 3.81M | 3.41M | 4.73M |
| Long-Term Debt | 24.93M | 25.13M | 0 | 0 | 107K | 2.1M | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 1.5M | 5.39M | 2.22M | 1.01M | 155K | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3M | 3M | 3M | 8.15M | 16.94M | 4.99M | 5.46M | 2.81M | 3.26M | 4.73M |
| Total Liabilities | 34.02M | 34.38M | 8.56M | 11.21M | 24.25M | 18.8M | 12.72M | 8.02M | 7M | 7.29M |
| Total Debt | 24.93M | 25.13M | 0 | 0 | 2.24M | 9.35M | 3.29M | 2.02M | 1.01M | 155K |
| Net Debt | 957K | 23.11M | -9.13M | -12M | -6.18M | -4.69M | -25.39M | -18.63M | -5.51M | -4.09M |
| Debt / Equity | 0.62x | 1.13x | - | - | 0.27x | 0.33x | 0.11x | 0.10x | 0.08x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -5.86x | -14.12x | -19.16x | -6.60x | -3876.20x | -271.87x | -1776.30x | - | - | - |
| Total Equity | 40.23M | 22.2M | 8.01M | 12.81M | 8.33M | 28.55M | 31.2M | 20.9M | 12.7M | 6.22M |
| Equity Growth % | 22.34% | -0.45% | -0.64% | 0.6% | -0.35% | 2.43% | 0.09% | -0.33% | -0.39% | -0.51% |
| Book Value per Share | 1126.81 | 400.27 | 148.54 | 136.10 | 52.34 | 114.68 | 58.64 | 34.87 | 10.27 | 4.56 |
| Total Shareholders' Equity | 40.23M | 22.2M | 8.01M | 12.81M | 7.71M | 27.73M | 31.09M | 21.03M | 12.84M | 6.22M |
| Common Stock | 44K | 44K | 42K | 45K | 49K | 54K | 63K | 65K | 65K | 65K |
| Retained Earnings | -131.93M | -151.55M | -167.26M | -178.37M | -207.17M | -211.82M | -226.49M | -257.86M | -271.84M | -278.88M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -115K | -19K | -1K | -4.8M | 1K | 0 | 0 | 0 | 101K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 621K | 827K | 103K | -133K | -138K | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -15.11M | -17.05M | -13.96M | -13.63M | -17.2M | -30.22M | -25.87M | -13.98M | -15.29M | -9.63M |
| Operating CF Margin % | -2.79% | -5.35% | -3.47% | -9.31% | -14.71% | -3.76% | -3.82% | -1.88% | -3.43% | -1.91% |
| Operating CF Growth % | -0.02% | -0.13% | 0.18% | 0.02% | -0.26% | -0.76% | 0.14% | 0.46% | -0.09% | 0.37% |
| Net Income | -17.96M | -19.62M | -15.71M | -13.48M | -28.87M | -6.03M | -16.13M | -15.61M | -13.99M | -4.32M |
| Depreciation & Amortization | 294K | 304K | 279K | 154K | 194K | 662K | 1.04M | 479K | 287K | 765K |
| Stock-Based Compensation | 1.39M | 1.06M | 1.47M | 1.55M | 2.29M | 2.04M | 1.54M | 1.11M | 717K | 0 |
| Deferred Taxes | -123K | 144K | 812K | -5.45M | 9.37M | -107K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 1.34M | 198K | 98K | 2.56M | -299K | -15.33M | -9.4M | -1M | 432K | -4.63M |
| Working Capital Changes | -53K | 864K | -921K | 1.04M | 123K | -11.46M | -2.92M | 1.05M | -2.74M | -1.45M |
| Change in Receivables | 336K | 357K | -882K | 1.07M | -437K | -1.12M | -40K | 592K | 184K | -762K |
| Change in Inventory | 412K | 582K | 183K | 160K | -1.53M | -9.75M | -2.38M | 1.12M | -2.42M | 550K |
| Change in Payables | 125K | -19K | 87K | 176K | 2.1M | -580K | -372K | -757K | -522K | -303K |
| Cash from Investing | -46.36M | -5.3M | 47.18M | -5.97M | -8.37M | 17.28M | 16.61M | 1.42M | -4.34M | 7.34M |
| Capital Expenditures | -151K | -231K | -79K | -250K | -1.48M | -2.33M | -1.01M | -72K | -5K | -2.02M |
| CapEx % of Revenue | 0.03% | 0.07% | 0.02% | 0.17% | 1.26% | 0.29% | 0.15% | 0.01% | 0% | 0.4% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 10K | -5.07M | 4K | 10K | -689K | 8K | 19K | 920K | 115K | 4M |
| Cash from Financing | 68.87M | 396K | -26.1M | 22.48M | 21.99M | 20.56M | 21.9M | 4.52M | 5.51M | 9K |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | -197K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | -9.56M | 396K | -1.1M | 12.48M | 14.49M | 9.49M | -1.1M | -481K | -485K | 0 |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -15.26M | -17.29M | -14.04M | -13.88M | -18.68M | -32.55M | -26.88M | -14.05M | -15.3M | -9.64M |
| FCF Margin % | -2.82% | -5.42% | -3.49% | -9.48% | -15.98% | -4.05% | -3.96% | -1.89% | -3.43% | -1.91% |
| FCF Growth % | -0.02% | -0.13% | 0.19% | 0.01% | -0.35% | -0.74% | 0.17% | 0.48% | -0.09% | 0.37% |
| FCF per Share | -427.47 | -311.70 | -260.53 | -147.42 | -117.40 | -130.75 | -50.52 | -23.44 | -12.37 | -7.07 |
| FCF Conversion (FCF/Net Income) | 0.84x | 0.87x | 0.89x | 1.01x | 0.60x | 6.49x | 1.76x | 0.91x | 1.09x | 1.37x |
| Interest Paid | 2.05M | 1.03M | 746K | 0 | 4K | 10K | 25K | 1K | 0 | 0 |
| Taxes Paid | 149K | 29K | 2K | 34K | 2K | 1K | 1K | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -93.67% | -62.87% | -104% | -129.48% | -272.5% | -25.25% | -49.07% | -59.03% | -83.21% | -74.37% |
| Return on Invested Capital (ROIC) | -62.75% | -32.29% | -48.59% | -1548.65% | -980.49% | -73.69% | -179.62% | -260.1% | -96.7% | -58.66% |
| Gross Margin | 83.52% | 71.93% | 92.97% | 54.85% | 24.29% | 35.29% | -28.44% | 17.75% | 51.19% | 41.27% |
| Net Margin | -331.66% | -615.56% | -390.14% | -920.76% | -2464.07% | -57.94% | -216.22% | -207.28% | -313.9% | -139.5% |
| Debt / Equity | 0.62x | 1.13x | - | - | 0.27x | 0.33x | 0.11x | 0.10x | 0.08x | 0.02x |
| Interest Coverage | -5.86x | -14.12x | -19.16x | -6.60x | -3876.20x | -271.87x | -1776.30x | - | - | - |
| FCF Conversion | 0.84x | 0.87x | 0.89x | 1.01x | 0.60x | 6.49x | 1.76x | 0.91x | 1.09x | 1.37x |
| Revenue Growth | -22.46% | -41.12% | 26.29% | -63.64% | -20.15% | 587.25% | -15.61% | 9.41% | -39.96% | 13.27% |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Product | - | - | 657K | 814K | 1.04M | 6.59M | 8.96M | 5.31M | 5.01M |
| Product Growth | - | - | - | 23.90% | 28.26% | 530.94% | 36.03% | -40.70% | -5.67% |
| Royalty | - | - | - | - | 83K | 176K | 117K | - | 26K |
| Royalty Growth | - | - | - | - | - | 112.05% | -33.52% | - | - |
| License | - | - | 150K | 67K | 6.8M | 17K | 879K | 17K | 7K |
| License Growth | - | - | - | -55.33% | 10050.75% | -99.75% | 5070.59% | -98.07% | -58.82% |
| Contract Research And Government Grants | - | - | 657K | 288K | 106K | - | - | - | - |
| Contract Research And Government Grants Growth | - | - | - | -56.16% | -63.19% | - | - | - | - |
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|
| UNITED STATES | 2.71M | 1.59M | 1.17M | 722K | 761K | 6M | 8.84M | 5.03M | 4.9M |
| UNITED STATES Growth | - | -41.51% | -26.45% | -38.18% | 5.40% | 688.83% | 47.19% | -43.05% | -2.56% |
| CANADA | 202K | 181K | 91K | 258K | 354K | 503K | 194K | 291K | 109K |
| CANADA Growth | - | -10.40% | -49.72% | 183.52% | 37.21% | 42.09% | -61.43% | 50.00% | -62.54% |
| ARGENTINA | - | - | - | - | 6.68M | 26K | 862K | - | 26K |
| ARGENTINA Growth | - | - | - | - | - | -99.61% | 3215.38% | - | - |
| INDIA | - | 1.06M | 90K | 7K | 100K | 7K | 7K | 7K | 7K |
| INDIA Growth | - | - | -91.54% | -92.22% | 1328.57% | -93.00% | 0.00% | 0.00% | 0.00% |
| GERMANY | - | - | - | - | - | - | 57K | - | - |
| GERMANY Growth | - | - | - | - | - | - | - | - | - |
| SPAIN | - | - | - | - | - | 225K | - | - | - |
| SPAIN Growth | - | - | - | - | - | - | - | - | - |
| Africa | 353K | 315K | 115K | 182K | 106K | - | - | - | - |
| Africa Growth | - | -10.76% | -63.49% | 58.26% | -41.76% | - | - | - | - |
| AUSTRIA | - | - | - | - | 32K | - | - | - | - |
| AUSTRIA Growth | - | - | - | - | - | - | - | - | - |
| CHINA | - | 586K | - | - | - | - | - | - | - |
| CHINA Growth | - | - | - | - | - | - | - | - | - |
| FRANCE | 18K | 220K | - | - | - | - | - | - | - |
| FRANCE Growth | - | 1122.22% | - | - | - | - | - | - | - |
| BELGIUM | - | 72K | - | - | - | - | - | - | - |
| BELGIUM Growth | - | - | - | - | - | - | - | - | - |
Arcadia Biosciences, Inc. (RKDA) reported $5.2M in revenue for fiscal year 2024. This represents a 26% decrease from $7.0M in 2012.
Arcadia Biosciences, Inc. (RKDA) grew revenue by 13.3% over the past year. This is steady growth.
Arcadia Biosciences, Inc. (RKDA) reported a net loss of $5.1M for fiscal year 2024.
Arcadia Biosciences, Inc. (RKDA) has a return on equity (ROE) of -74.4%. Negative ROE indicates the company is unprofitable.
Arcadia Biosciences, Inc. (RKDA) had negative free cash flow of $6.1M in fiscal year 2024, likely due to heavy capital investments.